Abstract: The present invention discloses a new series of host materials for OLEDs based on fused benzimidazolobenzimidazoles and indolocarbazoles. These compounds may be useful for improving device EQE and lifetime.

Abstract: The present invention relates to organic light emitting elements, comprising thermally activated delayed fluorescence (TADF) emitters and/or hosts on basis of benzotriazoles, which have a sufficiently small energy gap between S1 and T1 (?EST) to enable up-conversion of the triplet exciton from T1 to S1. The organic light emitting elements show high electroluminescent efficiency.

Abstract: The present invention relates to organic light emitting elements, comprising thermally activated delayed fluorescence (TADF) emitters and/or hosts on basis of benzotriazoles, which have a sufficiently small energy gap between S1 and T1 (?EST) to enable up-conversion of the triplet exciton from T1 to S1. The organic light emitting elements show high electroluminescent efficiency.

Abstract: The organic EL material is represented by Formula (1): where X1 to X4 are each independently a nitrogen (N) atom or a carbon atom that is monovalently bonded to R1(C—R1), R1 is a hydrogen atom, a halogen atom, an aryl group having 6 to 18 carbon atoms, a hetero aryl group having 6 to 18 carbon atoms, or an alkyl group having 1-12 carbon atoms, R2 to R10 are each independently hydrogen, an aryl group having 6 to 30 carbon atoms, or hetero aryl group having 6 to 30 carbon atoms, and at least one of X1 to X4 is a nitrogen atom.

Abstract: A compound having an indolocarbazole ring structure is represented by the following general formula (1), and is used as a material for forming a highly efficient and highly durable organic electroluminescent device. The compound features excellent hole injection/transport capability, has electron blocking power and is highly stable in the form of a thin film. wherein, A is a divalent aromatic hydrocarbon group or aromatic heterocyclic group, Ar1 to Ar4 are monovalent aromatic hydrocarbon groups or aromatic heterocyclic groups, and R1 to R9 are hydrogen atoms, deuterium atoms, fluorine atoms, chlorine atoms, cyano groups, nitro groups, alkyl groups, cycloalkyl groups, alkenyl groups, alkyloxy groups, cycloalkyloxy groups, aromatic hydrocarbon groups, aromatic heterocyclic groups or aryloxy groups.

Abstract: The present invention relates to the use of the vinyl quinuclidine enantiomer (R) of the following formula 2 as a synthesis intermediate in the preparation of (R)-mequitazine.

Abstract: The present invention relates to a compound according to formula (I), to the use thereof in an electronic device and to an electronic device which comprises one or more compounds according to formula (I).

Abstract: Use of rylene derivatives I with the following definition of the variables: X together both —COOM; Y a radical -L-NR1R2??(y1) -L-Z—R3??(y2) the other radical hydrogen; together both hydrogen; R is optionally substituted (het)aryloxy, (het)arylthio; P is —NR1R2; B is alkylene; optionally substituted phenylene; combinations thereof; A is —COOM; —SO3M; —PO3M2; D is optionally substituted phenylene, naphthylene, pyridylene; M is hydrogen; alkali metal cation; [NR5]4+; L is a chemical bond; optionally indirectly bonded, optionally substituted (het)arylene radical; R1, R2 are optionally substituted (cyclo)alkyl, (het)aryl; together optionally substituted ring comprising the nitrogen atom; Z is —O—; —S—; R3 is optionally substituted alkyl, (het)aryl; R? is hydrogen; optionally substituted (cyclo)alkyl, (het)aryl; R5 is hydrogen; optionally substituted alkyl (het)aryl; m is 0, 1, 2; n, p m=0: 0, 2, 4 where: n+p=2, 4, if appropriate 0; m=1: 0, 2, 4 where: n+p=0, 2, 4; m=2: 0, 4, 6

Abstract: The invention relates to a 1-aza-bicyclo[2.2.2]oct-2-en-3-ylmethyl acetate of the formula (I), wherein said compound is useful as a synthesis intermediate for the production of mequitazine.

Abstract: The present invention relates to fluorine derivatives and organic electronic devices in which said compounds are used as a matrix material in the emitting layer and/or as a hole transport material, and/or as an electron blocking or exciton blocking material, and/or as an electron transport material.

Abstract: This invention pertains to a class of autophagy inducing compounds that treat diseases caused by misfolded protein aggregates and a screening method for identifying these compounds.

Abstract: The invention relates to a 1-aza-bicyclo[2.2.2]oct-2-en-3-ylmethyl acetate of the formula (I), wherein said compound is useful as a synthesis intermediate for the production of mequitazine.

Abstract: The invention relates to compounds according to general formula (1) and/or their enantiomers, diastereomers as well as their pharmaceutically compatible salts, and to the use thereof for producing a medicament suited for treating diseases associated with misfolded proteins.

Abstract: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic ?-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.

Abstract: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic ?-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.

Abstract: The present invention relates to crystalline R-guanidines of (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, its preparations and its use as therapeutic agents. More specifically the present invention relates to crystalline Arginine (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, preferably (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, its preparation and its use as therapeutic agent.

Abstract: Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

Abstract: The present invention relates to 1,7 disubstituted guanines inhibitors possessing antitumor activity and to a process for preparing the same. Furthermore, these compounds are expected to enhance the efficacy of other chemotherapeutic agents, in the treatment of cancer.

Abstract: A chromene compound which develops yellow to red color, a high color density and a little initial color and which, when used in combination with an existing photochromic compound that exhibits blue color so as to develop a neutral tint, maintains uniformity in the color tone at the time of developing color or fading color, or exhibits a very large color fading rate.

Abstract: A compound of Formula (Ih) The compounds may be used, inter alia, for preparing beta aryl-alpha-oxy substituted alkylcarboxylic acids.

Abstract: The invention provides a novel heterocyclic ring condensed benzothiazine compound which is effective for prevention or remedy of disease, in which histamine, leukotriene and the like participate. The heterocyclic ring condensed benzothiazine compound of the present invention or a pharmacologically acceptable salt thereof is effective for prevention or remedy of disease, in which a chemical mediator, such as histamine, leukotriene and the like, participate, for example, asthma, allergic coryza, atopic dermatitis, hives, hay fever, gastrointestinal allergy, food allergy and the like.

Abstract: The invention provides compounds of Formula I: 1

Abstract: A compound of Formula (Ig) The compounds may be used, inter alia, for preparing beta aryl-alpha-oxy substituted alkylcarboxylic acids.

Abstract: A chromene compound which develops yellow to red color, a high color density and a little initial color and which, when used in combination with an existing photochromic compound that exhibits blue color so as to develop a neutral tint, maintains uniformity in the color tone at the time of developing color or fading color, or exhibits a very large color fading rate.

Abstract: A compound of formula (1) it derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, processes for its preparation and methods of use thereof.

Abstract: According to the method of the present invention, an alkali metal compound, dimethyl sulfoxide, trimethyloxosulfonium halide and 3-quinuclidinone are added in a specific order to give the following compound [II]. This compound is, without treatment or isolation, directly reacted with an alkali metal salt of phenothiazine to give the following compound [III], from which the following compound [I] is obtained. During the production of compound [I], a by-produced acidic gas is removed and water is added to ensure industrial, safe and efficient production of compound [I] at a constantly high yield. Inasmuch as the present invention enables production of the following highly pure compound [A] by eliminating hydrogen halide of compound [I] in glyme in the presence of at least one kind of a base selected from potassium hydroxide and potassium alkoxide, compound [A] having a high purity of not less than 85 mol % can be provided.

Abstract: A compound of formula (I) ##STR1## its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts or its pharmaceutically acceptable solvates, wherein R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are the same or different; R.sup.1 and R.sup.2 together represent along with carbon atoms to which they are attached an aromatic cyclic structure containing 5-6 ring atoms which may optionally be substituted; X represents a heteroatom selected from oxygen or sulfur; R.sup.7 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl group or optionally substituted aralkyl group or forms a bond together with R.sup.8 ; R.sup.8 represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl group or optionally substituted aralkyl or R.sup.8 forms a bond together with R.sup.

Abstract: Novel .beta.-aryl-.alpha.-oxysubstituted alkylcarboxylic acids of the formula (I) and compositions containing them. ##STR1## The compounds have hypolipidemic, antihyperglycemic uses.

Abstract: The compounds are trisubstituted triazines and pyrimidines useful for the suppressing the resistance of tumour cells to anti-cancer agents and for suppressing the resistance of parasites to anti-parasitic agents.A compound disclosed is 2,4-diallylamino-6-{4-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl) methylamino]piperidin-1-yl}-1,3,5-triazine.

Abstract: Novel pyrrolizidine compounds represented by the formula ##STR1## wherein R is a radical of ##STR2## R.sup.1 is hydrogen, halogen, alkyl group, alkoxy group, alkanoyl group, trifluoromethyl radical, trimethylsilyl radical or ##STR3## R.sup.2 and R.sup.3 are same or different and are hydrogen or alkyl group, respectively, R.sup.4 is hydrogen, halogen, alkyl group or alkoxy group and m is an integer of 0 to 5,salts thereof, a process for the preparation of same as well as a pharmaceutical agent comprising same.

Abstract: The present invention relates to compounds of the formula (I): ##STR1## or a salt, ester or amide thereof; wherein R.sup.1 is a C.sub.1-7 bivalent aliphatic hydrocarbon group or a single bond;R.sub.2 and R.sub.3 are the same or different and are each hydrogen, C.sub.1-4 alkyl or taken together with the nitrogen comprise a nitrogen-containing heterocyclic ring having four to six ring members;R.sup.4 is hydrogen, halogen, C.sub.1-4 alkoxy, C.sub.1-4 alkyl optionally substituted by one to three halogen atoms; or a group R.sub.1 CO.sub.2 H as hereinbefore defined; andA is C.sub.1-4 alkylene or ANR.sub.2 R.sub.3 forms a group --CH.sub.2 --(CH.sub.2).sub.2 or CH.sub.2 --(CH.sub.2).sub.2B is an acidic group other than a mono-carboxylic acid group of comparable or greater acid strength than a carboxylic acid group in a similar chemical environment, provided that any sulphonamide group contains at least one N-H bond.

Abstract: This invention describes tricyclic derivatives which are useful as histamine H.sub.1 -antagonists. A particular compound of this invention is 3-[3-(pyrido[3,2-b][1,4]-benzothiazin-10-yl)propylamino]-4-(pyrid-4-ylmeth ylamino)-1,2,5-thiadiazole-1-oxide.

Abstract: Quarternized derivatives of mequitazine, particularly 3-(10-H-phenothiazine-methyl)-1-methyl-1-azoniabicyclo [2.2.2]-octane iodide, show powerful anti-bronchospastic activity if administered by inhalation.

Abstract: Substituted (10H-phenothiazin-10-yl)propyl-1-piperazines of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, A, X, m, n and s are as hereinafter set forth,are described. The compounds of formula I, which contain a piperazine moiety combined by an ether linkage to different phenolic moieties, are useful as orally active long lasting antipsychotic agents.

Abstract: 10-[1-aza-(2,2,2)-bicyclo-3-octyl]-10H-2-phenothiazinesulfonamides of the formula: ##STR1## wherein R represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms are disclosed together with a process for their preparation. These compounds can be used as medicaments for the treatment of duodenal and gastric ulcers.

Abstract: Compounds of the general formula: ##STR1## in which either X represents an atom of sulfur and Y represents the N-oxide group or X represents the sulfinyl group or the sulfonyl group and Y represents an atom of nitrogen or the N-oxide group and their salts of addition with mineral or organic acids, their process of preparation and their use as a medicament for the treatment of gastric and duodenal ulcers.

Abstract: Tropyl derivatives of the formula: ##STR1## in which R.sup.1 is (a) phenyl linked through a direct bond, --O--, ##STR2## (in which m=2 or 3); (b) diphenylmethyl; or (c) 10H-phenothiazin-10-yl; (each of which type may be substituted, or unsubstituted); R.sup.2 is --H, --OH, or --O Si (CH.sub.3).sub.3 ; and R.sup.3 is substituted or unsubstituted phenyl, e.g. 4-[3-(4-fluorobenzoyl)-8-azabicyclo [3.2.1]oct-8-yl]-1-(-4-fluorophenyl)-1-butanone, in free base form or pharmaceutically acceptable acid addition salts are useful as pharmaceuticals.

Abstract: New phenothiazine derivatives having pharmaceutical activity are disclosed. The compounds are of particular interest because of their neuroleptic activity. The compounds are suitably prepared by reacting an N-substituted phenothiazine with an O,O'-isopropylidenyl-2-methyl-3-hydroxy-4-hydroxymethyl-5-(N-piperazinylme thyl)-pyridine.